Singapore, 18 April 2024— Horizon Quantum Computing, a company building software development tools for quantum computers, today announced that it is establishing a first-of-a-kind testbed for integrating quantum computing hardware with...
Curis (NASDAQ: CRIS) is the product of a three-way merger in 2000 of Pappas Capital portfolio company Reprogenesis with Creative Biomolecules and Ontogeny. The company was initially focused on regenerative medicine, but has evolved to become a leader in targeting signaling pathways – especially those involved in different cancers. The company’s so-called Hedgehog pathway inhibitor vismodegib is now being marketed in collaboration with Genentech.
Curis
Lexington, MA
NASDAQ
CRIS
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.